{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:41:14Z","timestamp":1760150474850,"version":"build-2065373602"},"reference-count":40,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The anterior pituitary gland comprises a heterogeneous population of pituitary cells [...]<\/jats:p>","DOI":"10.3390\/cancers15235526","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T08:47:43Z","timestamp":1700642863000},"page":"5526","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pituitary Tumors: Molecular Insights, Diagnosis, and Targeted Therapy"],"prefix":"10.3390","volume":"15","author":[{"given":"Kazunori","family":"Kageyama","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Aomori 036-8562, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4417-7476","authenticated-orcid":false,"given":"Mitsuru","family":"Nishiyama","sequence":"additional","affiliation":[{"name":"Health Care Center, Kochi University, 1-5-2 Akebono-cho, Kochi 780-8520, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1056\/NEJMra1810772","article-title":"Pituitary-tumor endocrinopathies","volume":"382","author":"Melmed","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Oh, J.Y., Osorio, R.C., Jung, J., Carrete, L., Choudhary, N., Lad, M., Saha, A., and Aghi, M.K. (2022). Transcriptomic profiles of normal pituitary cells and pituitary neuroendocrine tumor cells. Cancers, 15.","DOI":"10.3390\/cancers15010110"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000514862","article-title":"Pituitary tumors: Genetic and molecular factors underlying pathogenesis and clinical behavior","volume":"112","author":"Spada","year":"2022","journal-title":"Neuroendocrinology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/nrendo.2011.40","article-title":"Pathogenesis of pituitary tumors","volume":"7","author":"Melmed","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Tahara, S., Hattori, Y., Suzuki, K., Ishisaka, E., Teramoto, S., and Morita, A. (2022). An overview of pituitary incidentalomas: Diagnosis, clinical features, and management. Cancers, 14.","DOI":"10.3390\/cancers14174324"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Takayasu, S., Kageyama, K., and Daimon, M. (2023). Advances in molecular pathophysiology and targeted therapy for Cushing\u2019s disease. Cancers, 15.","DOI":"10.3390\/cancers15020496"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/ng.3166","article-title":"Mutations in the deubiquitinase gene USP8 cause Cushing\u2019s disease","volume":"47","author":"Reincke","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"E997","DOI":"10.1210\/jc.2015-1453","article-title":"The gene of the ubiquitin-specific protease 8 is frequently mutated in adenomas causing Cushing\u2019s disease","volume":"100","author":"Theodoropoulou","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/cr.2015.20","article-title":"Recurrent gain-of-function USP8 mutations in Cushing\u2019s disease","volume":"25","author":"Ma","year":"2015","journal-title":"Cell Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1677\/joe.1.05616","article-title":"Expression of epidermal growth factor receptor in neoplastic pituitary cells: Evidence for a role in corticotropinoma cells","volume":"183","author":"Theodoropoulou","year":"2004","journal-title":"J. Endocrinol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1172\/JCI60417","article-title":"EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas","volume":"121","author":"Fukuoka","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1507\/endocrj.EJ18-0491","article-title":"Lapatinib decreases the ACTH production and proliferation of corticotroph tumor cells","volume":"66","author":"Asari","year":"2019","journal-title":"Endocr. J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","article-title":"A 12-month phase 3 study of pasireotide in Cushing\u2019s disease","volume":"366","author":"Colao","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.mce.2018.12.022","article-title":"Somatostatin analogs regulate tumor corticotrophs growth by reducing ERK1\/2 activity","volume":"483","author":"Treppiedi","year":"2019","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.yfrne.2013.07.005","article-title":"Somatostatin receptors: From signaling to clinical practice","volume":"34","author":"Theodoropoulou","year":"2013","journal-title":"Front. Neuroendocrinol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1530\/ERC-22-0088","article-title":"Improved pasireotide response in USP8 mutant corticotroph tumours in vitro","volume":"29","author":"Albani","year":"2022","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/nm.3776","article-title":"A C-terminal HSP90 inhibitor restores glucocorticoid sensitivity and relieves a mouse allograft model of Cushing disease","volume":"21","author":"Riebold","year":"2015","journal-title":"Nat. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1007\/s11102-014-0607-4","article-title":"Inhibition of heat shock protein 90 decreases ACTH production and cell proliferation in AtT-20 cells","volume":"18","author":"Sugiyama","year":"2015","journal-title":"Pituitary"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1507\/endocrj.EJ15-0369","article-title":"Inhibitory effects of trichostatin A on adrenocorticotropic hormone production and proliferation of corticotroph tumor AtT-20 cells","volume":"62","author":"Nakada","year":"2015","journal-title":"Endocr. J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1210\/jc.2017-00464","article-title":"Histone deacetylase inhibitor SAHA is a promising treatment of Cushing disease","volume":"102","author":"Lu","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1158\/1535-7163.MCT-07-0560","article-title":"Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models","volume":"7","author":"Liu","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"170441","DOI":"10.1016\/j.peptides.2020.170441","article-title":"Involvement of histone deacetylase 1\/2 in adrenocorticotropic hormone synthesis and proliferation of corticotroph tumor AtT-20 cells","volume":"136","author":"Hagiwara","year":"2021","journal-title":"Peptides"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1507\/endocrj.EJ21-0778","article-title":"Effects of tubastatin A on adrenocorticotropic hormone synthesis and proliferation of AtT-20 corticotroph tumor cells","volume":"69","author":"Hagiwara","year":"2022","journal-title":"Endocr. J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/eje.0.143r001","article-title":"Cyclin D and cyclin E expression in normal and adenomatous pituitary","volume":"143","author":"Jordan","year":"2000","journal-title":"Eur. J. Endocrinol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1210\/jcem.84.10.6066","article-title":"Low expression of the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors","volume":"84","author":"Lidhar","year":"1999","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1210\/me.2010-0091","article-title":"Cooperation between cyclin E and p27(Kip1) in pituitary tumorigenesis","volume":"24","author":"Bilodeau","year":"2010","journal-title":"Mol. Endocrinol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"8414","DOI":"10.1073\/pnas.1018091108","article-title":"Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor","volume":"108","author":"Liu","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1210\/jc.2015-1606","article-title":"Cyclin E-mediated human proopiomelanocortin regulation as a therapeutic target for Cushing disease","volume":"100","author":"Liu","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Yamamoto, M., and Takahashi, Y. (2022). Genetic and epigenetic pathogenesis of acromegaly. Cancers, 14.","DOI":"10.3390\/cancers14163861"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Ling, C., Pease, M., Shi, L., Punj, V., Shiroishi, M.S., Commins, D., Weisenberger, D.J., Wang, K., and Zada, G. (2014). A pilot genome-scale profiling of DNA methylation in sporadic pituitary macroadenomas: Association with tumor invasion and histopathological subtype. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0096178"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"787","DOI":"10.3171\/2019.12.JNS192435","article-title":"Role of KCNAB2 expression in modulating hormone secretion in somatotroph pituitary adenoma","volume":"134","author":"Ashton","year":"2020","journal-title":"J. Neurosurg."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Ferr\u00e9s, A., Reyes, L., Di Somma, A., Topczewski, T., Mosteiro, A., Guizzardi, G., De Rosa, A., Halperin, I., Hanzu, F., and Mora, M. (2022). The prognostic-based approach in growth hormone-secreting pituitary neuroendocrine tumors (PitNET): Tertiary reference center, single senior surgeon, and long-term follow-up. Cancers, 15.","DOI":"10.3390\/cancers15010267"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Fukuhara, N., Nishiyama, M., and Iwasaki, Y. (2022). Update in pathogenesis, diagnosis, and therapy of prolactinoma. Cancers, 14.","DOI":"10.3390\/cancers14153604"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/cen.14727","article-title":"Update on the clinical management of multiple endocrine neoplasia type 1","volume":"97","author":"Pieterman","year":"2022","journal-title":"Clin. Endocrinol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000371819","article-title":"MEN1, MEN4, and Carney complex: Pathology and molecular genetics","volume":"103","author":"Trivellin","year":"2016","journal-title":"Neuroendocrinology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"684","DOI":"10.4158\/EP-2018-0321","article-title":"The effect of raloxifene on serum prolactin level in patients with prolactinoma","volume":"25","author":"Choudhary","year":"2019","journal-title":"Endocr. Pract."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e917","DOI":"10.1210\/clinem\/dgaa805","article-title":"EGFR\/ErbB2-targeting lapatinib therapy for aggressive prolactinomas","volume":"106","author":"Cooper","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1210\/jc.2018-02461","article-title":"Effect of everolimus in treatment of aggressive prolactin-secreting pituitary adenomas","volume":"104","author":"Zhang","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Matsumoto, R., Suga, H., Arima, H., and Yamamoto, T. (2022). Disease modeling of pituitary adenoma using human pluripotent stem cells. Cancers, 14.","DOI":"10.3390\/cancers14153660"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nature10637","article-title":"Self-formation of functional adenohypophysis in three-dimensional culture","volume":"480","author":"Suga","year":"2011","journal-title":"Nature"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/23\/5526\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:27:13Z","timestamp":1760131633000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/23\/5526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,22]]},"references-count":40,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["cancers15235526"],"URL":"https:\/\/doi.org\/10.3390\/cancers15235526","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2023,11,22]]}}}